Logo Image
News|Articles|April 23, 2014

PTSM: Pharmaceutical Technology Sourcing and Management

  • PTSM: Pharmaceutical Technology Sourcing and Management-05-07-2014
  • Volume 10
  • Issue 5

Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement

Author(s)Melanie Sena

Bristol-Myers Squibb and Samsung BioLogics expand their manufacturing agreement to cover biologic medicines.

Bristol-Myers Squibb and Samsung BioLogics have expanded their existing manufacturing agreement, in which Samsung will manufacture commercial drug substances and drug product for several Bristol-Myers Squibb biologic medicines at Samsung's Incheon, China manufacturing site. Financial terms of the agreement are not disclosed.

Bristol-Myers Squibb and Samsung announced their first manufacturing agreement in July 2013 to collaborate in the production of a single commercial antibody cancer drug substance.

Source: Bristol-Myers Squibb

Articles in this issue

over 12 years ago

Using eClinical Systems for Supply-Chain Management

over 12 years ago

Janssen Pharmaceutical Collaborates with Stiching International Dispensary Association

over 12 years ago

FDA and Industry Take Action for a More Secure Drug Supply Chain

over 12 years ago

Packaging Becomes Enabler for Biopharmaceuticals

over 12 years ago

Bristol-Myers Squibb Named First on 2014 Best Corporate Citizens List

over 12 years ago

Azzur Group and BioSPEQ Announce Merger

over 12 years ago

Eli Lilly Launches Second Education Program for Medical Students

over 12 years ago

Global Instability Impacts Brazil's Pharma Market

over 12 years ago

US Biopharma Worries About Losing Lead in Innovation

over 12 years ago

Outsourcing Remains Strong In Traditional Areas

Related Content